Core Insights - Alliance Creative Group, Inc. (ACGX) reported a gross income of $364,082 and a net income of $81,269 for the year ending December 31, 2025, indicating a focus on growth through technology-driven initiatives [1][3] - The company aims to build an integrated ecosystem of media, marketing, and AI-powered platforms to enhance traffic generation and shareholder value [3][9] Financial Performance - Total expenses for 2025 were $282,813, resulting in a net income margin of approximately 22.3% [1] - As of December 31, 2025, total assets were valued at $1,066,929, with cash on hand amounting to $65,249 [1][2] Strategic Developments - ACGX has developed internal AI capabilities aimed at automation and scalable marketing systems, enhancing its digital platform offerings [4] - The company has expanded its digital asset portfolio by acquiring multiple websites and social media platforms to drive traffic and monetization [4] Investment Strategy - ACGX maintains a significant equity position in PeopleVine, Inc., a SaaS platform, and is considering partial monetization of these shares to fund high-growth initiatives [5] - The company holds a 20% stake in Say Less Spritz, a premium ready-to-drink wine brand, indicating diversification in its investment portfolio [5] Operational Efficiency - ACGX operates with a lean cost structure and minimal fixed overhead, allowing for flexibility in pursuing new opportunities [7] - The company has established a shared-resource model to enhance efficiency and margins across its projects [7] Future Outlook - The long-term strategy of ACGX focuses on building a portfolio of digital assets, leveraging AI-driven automation, and creating multiple revenue streams [7][9] - The CEO emphasized that 2025 was a foundational year for transitioning to a scalable, technology-driven business model, positioning the company for growth in 2026 and beyond [3]

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- Reconnaissance Energy Africa Ltd. (the “Company”, “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) (NSX: REC) is pleased to provide an update of its operations in Namibia and Gabon. Operational highlights: Production testing operations commenced at the Kavango West 1X discovery well;Increased hydrocarbon pay in the Huttenberg formation to 75 metres (259 feet);Isolated a total of 345 metres (1,132 feet) of prospective interval for testing;Reproc ...

Core Insights - KH Group has published its Annual Report for 2025, which includes the Board of Directors' Report, Financial Statements, Corporate Governance Statement, and the Governing Bodies' Remuneration Report [1][3] - The Financial Statements are available in an xHTML format in Finnish, complying with European Single Electronic Format (ESEF) reporting requirements, and have been audited by Ernst & Young Oy [2] Financial Reporting - The Financial Statements include primary statements and notes labeled with XBRL tags as per ESEF requirements [2] - An independent auditor's reasonable assurance report on the ESEF Financial Statements has been provided in accordance with ISAE 3000 (Revised) [2] Company Overview - KH Group operates in two business areas: KH-Koneet, which supplies construction and earth-moving machinery, and Nordic Rescue Group, a manufacturer of rescue vehicles [3] - The company's shares are listed on Nasdaq Helsinki, and further information can be found on their website [3]

Core Viewpoint - RenX Enterprises Corp. has confirmed the completion of the UTM 1200 Turbo Mill, which is set to enhance its biomass recycling capabilities and is expected to be operational by 2026 [1][4]. Group 1: Company Developments - The UTM 1200 Turbo Mill, part of a 12-step engineered processing circuit, can process up to 10 tons per hour of woody biomass and produce three specification-defined particle cuts [2]. - RenX has executed a comprehensive process flow and site engineering design, and has secured vendor commitments for essential equipment, including the Allgaier TSM 2000 tumbler screener and Sesotec RAPID PRO SENSE metal rejection system [3]. - The company has contracted for the installation of a reinforced concrete pad and procured shipping containers for operational support [3]. Group 2: Project Phases - The deployment of the Microtec system will occur in phases, with the initial phase focusing on the UTM 1200 milling line expected to be operational in 2026 [4]. - Subsequent phases will include an automated bagging line and a soil blending line, projected to begin no earlier than 2027 [4]. Group 3: Operational Strategy - RenX operates a vertically integrated environmental services platform, focusing on engineered soils, organic recycling, and bulk materials logistics [7]. - The company aims to optimize products for regional feedstocks and customer requirements, enhancing quality control and improving unit economics [8].

Core Viewpoint - CDT Equity Inc. has filed two new patent applications to expand its intellectual property portfolio related to tapinarof, a drug approved for psoriasis and atopic dermatitis, potentially enhancing its clinical and commercial scope [1][2]. Group 1: Patent Applications - The first patent application covers a combination therapy of tapinarof with other clinically proven drugs for psoriasis and atopic dermatitis [2]. - The second patent application relates to novel cocrystal forms of tapinarof with these agents, which may lead to a second-generation product with improved formulation properties and efficacy [2]. Group 2: Market Trends and Opportunities - Following Organon's $1.2 billion acquisition of Dermavant in 2024, there is a growing demand for second-generation topical therapies as alternatives to oral and injectable treatments for skin conditions [3]. - The combination therapies identified through Sarborg Limited's Signature Agent platform may improve outcomes in existing dermatological markets and highlight opportunities in underserved conditions [4]. Group 3: Efficacy and Strategic Development - Tapinarof has shown clinical efficacy in treating psoriasis and atopic dermatitis, and the new combinations may enhance efficacy by targeting multiple disease pathways [5]. - The company aims to leverage artificial intelligence-driven analysis for targeted intellectual property development and pursue out-licensing opportunities with pharmaceutical companies [6]. Group 4: Company Overview - CDT Equity Inc. is a biopharmaceutical development company focused on advancing high-potential therapeutic assets through scientific innovation and strategic partnerships [8]. - The company is committed to creating shareholder value through licensing, strategic mergers and acquisitions, and positioning itself as a platform for transformative innovation [8].

Core Viewpoint - Perma-Fix Environmental Services, Inc. has been awarded a two-year master task agreement valued at approximately $24 million by Lawrence Livermore National Security, LLC for demolition and disposal services at Lawrence Livermore National Laboratory, reinforcing its long-standing relationship with LLNS [1][4]. Group 1: Project Details - The agreement involves providing demolition, excavation, and waste management services to support the safe disposition of facilities aligned with LLNL's national security mission [2]. - The project will leverage Perma-Fix's expertise in complex radiological and hazardous waste handling, facility decontamination, and nuclear waste management [2]. Group 2: Execution Strategy - Perma-Fix will collaborate with three local subcontractors to ensure safe demolition and disposal while minimizing impacts on surrounding operations [3]. - The company aims to support LLNS's performance objectives through disciplined project execution, risk management, and close coordination with site stakeholders [3]. Group 3: Company Background - Perma-Fix Environmental Services is a leading provider of nuclear and mixed waste management services, including management and treatment of radioactive waste for various federal agencies and the commercial nuclear industry [5]. - The company operates four nuclear waste treatment facilities and provides a range of nuclear services, including project management, environmental restoration, and radiological protection [5].

Core Viewpoint - SEALSQ Corp is positioned to support the Wi-SUN Alliance in addressing quantum computing threats to smart energy infrastructure through its advanced post-quantum cryptography solutions and Public Key Infrastructure services [1][2][5]. Group 1: Company Capabilities - SEALSQ offers advanced post-quantum chips and comprehensive PKI services, enabling the development of transition roadmaps for quantum resilience in smart meter ecosystems [1][3]. - The QS7001 secure System-on-Chip (SoC) and QVault Trusted Platform Module (TPM) integrate hardware roots of trust with post-quantum cryptography capabilities, essential for secure device identity management and cryptographic agility [3][9]. - SEALSQ's INeS PKI platform provides scalable device identity management, secure provisioning, and certificate lifecycle handling, which are critical for minimizing disruption during the transition to quantum resilience [3][9]. Group 2: Industry Collaboration - SEALSQ is actively collaborating with Wi-SUN Alliance members, including Landis+Gyr, to enhance network security and meet regulatory requirements for advanced metering infrastructure [4][5]. - The company emphasizes the importance of collaboration across standards bodies and industry leaders to address quantum threats effectively [5][8]. - SEALSQ will participate in the Wi-SUN Open House 2026, focusing on advancements in Wi-SUN technologies and strategies for building quantum-resilient compliance [5][6]. Group 3: Market Context - The smart energy sector, particularly Wi-SUN-compliant networks, faces risks from quantum computing, necessitating proactive measures for cryptographic migrations [2][8]. - SEALSQ's solutions are designed to protect sensitive data across various applications, including smart energy, healthcare, and automotive sectors, ensuring resilience against quantum threats [9].

Core Insights - Emory Healthcare has successfully performed the world's first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer using Microbot Medical's LIBERTY® Endovascular Robotic System, showcasing the system's versatility across various medical procedures [1][3][4] Company Overview - Microbot Medical is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY® Endovascular Robotic System being the first FDA-cleared single-use, remotely operated robotic solution designed for precision, efficiency, and safety [10] Product Details - The LIBERTY System allows for minimally invasive treatments, improving efficiency in reaching treatment sites within blood vessels due to its fine motor control capabilities [5] - The system is designed to reduce radiation exposure and physical strain on clinicians while enhancing procedural efficiency [7] Market Potential - The LIBERTY System aims to establish endovascular robotic navigation as the standard of care for PAE in patients with enlarged prostates, similar to the adoption of robotic-assisted prostatectomy for prostate cancer [4] - Approximately 40 million men in the U.S. are affected by BPH, indicating a significant patient population for the LIBERTY System [2] Recent Developments - Microbot Medical commenced the Limited Market Release of the LIBERTY system in November 2025 and plans for a Full Market Release at the Society of Interventional Radiology conference in April 2026, aiming to deepen market adoption [8]

Core Viewpoint - Pluri Inc. has announced a $2.5 million investment from Alejandro Weinstein, the Chairman of the Board, at a 30% premium to the market price, indicating strong confidence in the company's strategy and long-term value creation [1][2][3] Investment Details - The investment follows a previous $2.5 million investment by Mr. Weinstein upon his appointment as Chairman, highlighting his ongoing support for Pluri's strategy and asset base [2] - The Securities Purchase Agreement involves a private placement of 625,000 common shares at a price of $4.00 per share, along with warrants to purchase an additional 625,000 shares at an exercise price of $4.25 [3] - The total gross proceeds from this transaction are expected to be approximately $2.5 million, which will be used for general working capital and corporate purposes [3] Company Overview - Pluri Inc. is a biotechnology company specializing in mass-scale cell expansion and biofarming, utilizing a proprietary 3D cell expansion platform [7] - The company focuses on innovation in regenerative medicine, food technology, and agricultural technology, aiming to address global challenges such as sustainable food production and healthcare [8]

Group 1 - The core focus of DeFi Development Corp. is its treasury strategy centered on accumulating and compounding Solana (SOL) [1][4] - The company successfully held a community Ask Me Anything (AMA) session on March 23, 2026, to engage with its community and investors [2][3] - Topics discussed during the AMA included the treasury strategy, developments in the Solana ecosystem, validator operations, digital asset treasury expansion, and ongoing product innovation [2] Group 2 - DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake, while also holding and staking SOL [4] - The company is actively involved in decentralized finance (DeFi) opportunities and is exploring innovative ways to support the growth of Solana's application layer [4] - The company serves over one million web users annually, including property owners, developers, and various financial institutions, applying for billions of dollars in debt financing [6]